Clopidogrel Resistance Testing (CYP2C19) ₹9500

The Clopidogrel Resistance Testing (CYP2C19) is a pharmacogenomic genetic test that identifies variations in the CYP2C19 gene. These genetic variants can affect how your body activates Clopidogrel (Plavix®), helping doctors determine whether the medication is likely to work effectively or if an alternative antiplatelet therapy may be more appropriate.

Book on WhatsApp Call Now

Advanced Pharmacogenomic (PGx) Testing Available

Quick Details

Test Price ₹9500

Fasting Required No

Sample Type Blood / EDTA Blood

Report Time 5–10 Working Days*

What is Clopidogrel Resistance Testing (CYP2C19)?

The Clopidogrel Resistance Test analyzes the CYP2C19 gene, which produces an enzyme responsible for converting Clopidogrel into its active form. Certain inherited genetic variants reduce enzyme activity, making Clopidogrel less effective and increasing the risk of blood clots, heart attack, stroke, or stent thrombosis. This test helps doctors personalize antiplatelet therapy based on your genetic profile.

Who should consider this test?

Patients scheduled for coronary angioplasty (PCI) or stent placement.
Individuals prescribed Clopidogrel (Plavix®).
Patients with recurrent cardiovascular events despite Clopidogrel therapy.
Individuals with a history of heart attack, stroke, or peripheral artery disease.
Patients requiring personalized antiplatelet therapy.
Doctor-recommended pharmacogenomic testing before long-term Clopidogrel treatment.

Preparation & Test Process

Fasting

No fasting is required before sample collection.

Sample Type

A blood sample is collected in an EDTA tube for DNA analysis.

Method

Molecular genetic testing is performed to identify clinically significant CYP2C19 gene variants.

Important Note

Because genetic makeup does not change, this test is generally performed only once in a lifetime unless otherwise advised by your physician.

Understanding Your Results

The report classifies your ability to metabolize Clopidogrel based on your CYP2C19 genotype.

Possible metabolizer categories include:

Normal (Extensive) Metabolizer
Rapid or Ultra-Rapid Metabolizer
Intermediate Metabolizer
Poor Metabolizer

Patients identified as Intermediate or Poor Metabolizers may have reduced response to Clopidogrel, and their physician may consider alternative antiplatelet medications based on current clinical guidelines.

Results should always be interpreted by your cardiologist or clinical geneticist together with your medical history, medications, and cardiovascular risk profile.

FAQs – Clopidogrel Resistance Testing (CYP2C19)

CYP2C19 is a gene that produces an enzyme responsible for activating Clopidogrel. Genetic variations can affect how well the medication works.

It is commonly recommended for patients undergoing coronary stenting, those prescribed Clopidogrel, or individuals with suspected resistance to the medication.

No. Fasting is not required before sample collection.

No. Since your genetic profile remains the same throughout life, the test is generally performed only once.

Book on WhatsApp Call Now

Related diagnostic tests

CSF MICROPROTEIN CSF CRP CSF CHLORIDE CSF BIOCHEMISTRY cryptococcus serum

Book Clopidogrel Resistance Testing CYP2C19 in Chandigarh

Home collection · Digital reports · 24–48 hours

WhatsApp to book Call 7087015736

Disclaimer: This page is for informational purposes only. Consult your doctor for medical advice. All tests processed with NABL-aligned quality standards.